Skip to content
The BCI Briefing

Research initiativeCore BCI

BrainGate

The academic consortium behind two decades of human intracortical BCI research.

Location
Providence, United States
Founded
2004
Sources last checked
3 Oct 2026

What they are building

A multi-institution research programme running the BrainGate2 feasibility study of intracortical neural interfaces for people with tetraplegia.

Interface category
Intracortical arrays
Signal
Action potentials and local field potentials
Invasiveness
Invasive
Recording / stimulation
Recording and stimulation
Device
Utah array (NeuroPort) — Rigid silicon microelectrode array, typically connected through a skull-mounted pedestal
Channels
96 electrodes per array in most human studies
Regulatory status
Investigational for chronic BCI use
Main use cases
Communicate, Control, Move
Works with
Brown University / Providence VA Medical Center · Massachusetts General Hospital · Stanford University

Where they are clinically

Feasibility

Small early studies that test safety and whether the device can do what it is meant to.

Access today

Experimental human research

Demonstrated in a small number of research participants. Not an established treatment.

Shown in people
Two decades of peer-reviewed results: cursor control (2006), handwriting at 90 characters per minute (2021) and speech at 97.5% word accuracy over 8.4 months (2024).
Still an aim
It is a research programme and sells nothing. Its aim is evidence and methods that others build on.
What stands in the way
Research hardware: arrays wired through the skull, used with a study team's support.

On record here: 3 registered studies · 62 participants planned or enrolled · 7 peer-reviewed papers

This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.

Why this initiative matters

BrainGate is the field's reference programme. Its open publication record and released datasets set the benchmarks that commercial systems are now measured against, and its sites train many of the people who go on to build them. Its participants use arrays wired through the skull with a study team on hand, so the results show what is possible, not what a product delivers.

Key milestones

  1. 15 Aug 2024

    Speech neuroprosthesis sustains 97.5% accuracy over 8.4 months in one participant.

    Card NS et al., New England Journal of Medicine

  2. 12 May 2021

    Handwriting decoded at 90 characters per minute.

    Willett FR et al., Nature

  3. May 2009

    BrainGate2 feasibility study begins; it remains open across six US sites.

    BrainGate2 · NCT00912041

  4. 13 Jul 2006

    First report of a person with tetraplegia controlling a cursor and devices with an intracortical array.

    Hochberg LR et al., Nature

Clinical programmes

  • Interfacing with neurotechnology to expand neural throughput

    Academic study with Blackrock Neurotech as collaborator.

    FeasibilityRecruiting

    5 estimatedNCT07521930

  • CRS-BMI

    Bidirectional intracortical BCI: motor decoding with tactile feedback by microstimulation.

    FeasibilityRecruiting

    30 estimatedNCT01894802

  • BrainGate2

    The longest-running intracortical BCI study, open since 2009 across six US sites.

    FeasibilityRecruiting

    27 estimatedNCT00912041

Research

Leadership

  • Leigh R. Hochberg

    Sponsor-investigator, BrainGate2

As publicly stated by the organisation. Not a complete list.

Competitive context

Sources

  1. 01

    Hochberg LR et al. Nature 2006;442(7099):164–171 (opens in a new tab)

    Peer reviewedNature13 Jul 2006Checked against source 3 Oct 2026

    DOI 10.1038/nature04970

  2. 02

    ClinicalTrials.gov NCT00912041 (opens in a new tab)

    Clinical registryClinicalTrials.gov1 Jun 2026Checked against source 3 Oct 2026

    Registry record last updated 2026-06-01.

  3. 03

    Willett FR et al. Nature 2021;593(7858):249–254 (opens in a new tab)

    Peer reviewedNature12 May 2021Checked against source 3 Oct 2026

    DOI 10.1038/s41586-021-03506-2

  4. 04

    Card NS et al. N Engl J Med 2024;391(7):609–618 (opens in a new tab)

    Peer reviewedNew England Journal of Medicine15 Aug 2024Checked against source 3 Oct 2026

    DOI 10.1056/NEJMoa2314132